Core Viewpoint - Immunic, Inc. has appointed Jon Congleton, a biopharmaceutical executive with nearly 40 years of experience, to its Board of Directors, effective March 27, 2026, to support the company's transition into a fully integrated commercial-stage entity and advance its lead program, vidofludimus calcium, for multiple sclerosis [1][4]. Company Overview - Immunic, Inc. is a late-stage biotechnology company focused on developing novel oral therapies for neurologic diseases, with its lead program, vidofludimus calcium (IMU-838), currently in phase 3 clinical trials for relapsing multiple sclerosis [4][10]. - The company aims to provide innovative solutions for patients suffering from neurologic conditions, particularly multiple sclerosis, which remains a significant challenge for patients and their families [4]. Appointment of Jon Congleton - Jon Congleton has a proven track record in building and leading biopharmaceutical organizations, having played a key role in the U.S. launch of Teva Pharmaceuticals' Copaxone®, which became the number one prescribed treatment for multiple sclerosis [2][3]. - Congleton's experience includes serving as CEO of Mineralys Therapeutics, Impel NeuroPharma, and Nivalis Therapeutics, where he guided companies from early-stage to publicly traded entities [3]. Strategic Importance - The appointment of Congleton is seen as critical for advancing Immunic's lead program, vidofludimus calcium, which is expected to offer transformative benefits for multiple sclerosis patients due to its unique combination of neuroprotective, anti-inflammatory, and anti-viral effects [4]. - The company anticipates pivotal trial readouts later in the year, which are crucial for long-term value creation and potential regulatory approval [4]. Development Pipeline - In addition to vidofludimus calcium, Immunic's development pipeline includes earlier-stage programs such as IMU-856 and IMU-381, aimed at addressing neurodegenerative, chronic inflammatory, and autoimmune-related diseases [4].

Group 1 - Immunic, Inc. (NASDAQ:IMUX) has received a key patent from the European Patent Office for its lead asset, vidofludimus calcium, which is expected to provide protection in Europe until 2038, with potential extension to 2043 through a Supplementary Protection Certificate [1][2] - The patent claims cover vidofludimus and its various forms, ensuring broad protection across all label-relevant dosing regimens, not limited to a single formulation [2] - H.C. Wainwright has lowered its price target for Immunic, Inc. to $5 from $8 while maintaining a Buy rating, indicating a reassessment of the company's valuation [3]

Summary of Immunic Conference Call Company Overview - **Company**: Immunic - **Key Product**: Vidofludimus calcium, a drug in development for treating multiple sclerosis (MS) Industry Context - **Market**: Multiple Sclerosis (MS) treatment landscape, which includes various therapies with differing safety and efficacy profiles Key Points 2026 Outlook - 2026 is expected to be transformative for Immunic with the phase 3 readout of ENSURE-1 and ENSURE-2 studies planned for the end of the year [1] - NDA submission for vidofludimus calcium is planned for the following year [1] Drug Mechanism and Safety Profile - Vidofludimus calcium is designed as a safer and more selective DHODH inhibitor compared to Aubagio, avoiding off-target activities that lead to side effects [3][4] - The drug activates the nuclear receptor Nurr1, providing neuroprotective effects and solid anti-inflammatory activity [3][7] - Safety data indicates that vidofludimus calcium has a favorable liver toxicity profile compared to teriflunomide, with liver enzyme elevations comparable to placebo [10] - The elimination half-life of vidofludimus calcium is approximately 30 hours, allowing for quicker clearance compared to teriflunomide, which has a half-life of 10-19 days [11] Clinical Data and Efficacy - In the EMPhASIS study, vidofludimus calcium showed a 57% lower rate of confirmed disability progression compared to the control group [13] - The CALLIPER study indicated a 31% reduction in confirmed disability worsening in primary progressive MS (PPMS) patients [16] - The primary endpoint for upcoming studies will be time to first relapse, with secondary endpoints including confirmed disability progression and improvement [20] Market Positioning - Vidofludimus calcium aims to capture the oral medication segment, which constitutes 35%-40% of all prescriptions in the U.S. for MS [26] - The drug is positioned to address unmet needs in patients transitioning from CD20 therapies, which have serious infection risks [30] - The company believes that vidofludimus calcium will offer a best-in-class benefit-risk profile, particularly for patients preferring oral administration [27] Future Plans - A confirmatory study for PPMS is expected to start in the second half of the year, with an estimated duration of 3.5-4 years for enrollment and data readout [38] - The company anticipates significant market potential, estimating a multi-billion dollar upside for the PPMS indication [41] Conclusion - Immunic is optimistic about the upcoming data and believes that vidofludimus calcium could provide a new treatment option for individuals living with MS, addressing both relapsing and progressive forms of the disease [40][41]

Summary of Immunic's Conference Call Company Overview - **Company**: Immunic - **Product**: Vidofludimus calcium - **Focus**: Treatment for multiple sclerosis (MS) Key Points Unique Mechanism of Action - Vidofludimus calcium activates Nurr1, a nuclear receptor involved in neuroprotection, which differentiates it from other MS treatments [4][7] - It also acts as a DHODH inhibitor, providing an established anti-inflammatory mechanism [4][7] Clinical Data and Efficacy - The EMPHASIS study showed: - 76% reduction in cumulative active lesions - 78% reduction in gadolinium-enhancing lesions [20] - A numerical reduction of disability progression (CDW) by over 50% in the phase 2 study [14] - Safety and tolerability were comparable to placebo, indicating a favorable profile [21] Comparison with Other Treatments - Current oral therapies show efficacy rates of 30%-50% for glatiramer acetate and Aubagio, while anti-CD20 therapies show 80%-90% [22][24] - Vidofludimus calcium aims to provide a better benefit-risk profile, especially for patients who cannot tolerate existing therapies [43] Market Opportunity - The oral therapy market represents 35%-40% of total prescriptions for MS [77] - An estimated 5%-10% of patients on anti-CD20 therapies may need to switch due to serious infections, representing a potential $1 billion market in the U.S. alone [80][81] - The average cost of branded oral therapies is projected to be around $120,000 WAC at launch [85] Phase 3 Studies - The ENSURE studies for relapsing MS are fully enrolled, with primary endpoints focused on time to first relapse and secondary endpoints including MRI biomarkers and disability progression [57][58] - Expected readout for the studies is at the end of the year [62] Progressive MS Treatment - Immunic is also targeting primary progressive MS (PPMS) with a phase 2 study showing a 31% reduction in disability progression [112][113] - The potential market for PPMS is significant, with Roche's Ocrevus generating over $3 billion in sales from this segment [151] Safety Profile - Vidofludimus calcium has shown a clean safety profile with low rates of adverse events compared to existing therapies [46][48] - No significant liver enzyme changes were observed, differentiating it from other DHODH inhibitors [54] Future Outlook - Immunic plans to initiate pivotal studies for PPMS, with expectations of replicating positive data from previous studies [155] - The company believes it has a differentiated asset that could capture significant market share in both relapsing and progressive MS [161] Conclusion - Immunic is positioned to address unmet needs in the MS market with vidofludimus calcium, focusing on both relapsing and progressive forms of the disease, while emphasizing safety and tolerability as key differentiators [161]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across various financial markets [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights into sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Core Viewpoint - Immunic Inc has secured up to $400 million in private placement financing to support late-stage trials and prepare for the potential commercial launch of vidofludimus calcium for multiple sclerosis [1][2]. Financing Details - The financing is described as a transformative transaction, with $200 million already received and the remainder available in a second tranche [2][4]. - This capital provides the necessary flexibility for the company to transition into a commercial-stage organization as it approaches a pivotal data milestone [2][4]. Clinical Trials and Milestones - The primary near-term catalyst is the Phase 3 ENSURE program in relapsing multiple sclerosis (RMS), which includes two twin studies [3][6]. - An interim analysis in 2024 led to a recommendation from the Independent Data Monitoring Committee to continue the trials as planned [3][6]. - Topline data from the four-year, 2,200-patient program is expected by the end of the year [3][6]. Future Plans - The financing will cover the completion of the Phase 3 studies in relapsing MS and the preparation for a New Drug Application (NDA) submission in mid-next year [5]. - The company also plans to initiate a Phase 3 study in primary progressive MS, addressing a significant unmet medical need [5].

Core Insights - Immunic has successfully completed an oversubscribed private placement of up to $400 million, marking its transition from an R&D-focused organization to a commercial-stage entity [1] Funding and Financial Details - The private placement was led by existing investor BVF Partners, with participation from Avidity Partners, OrbiMed, Trails Edge Capital Partners, TCGX, Vivo Capital, and other institutional investors [1] - Under the terms of the private placement, Immunic will issue 229.1 million pre-funded warrants at a price of $0.873 per warrant, generating upfront proceeds of $200 million [4] - Investors will also receive warrants for an additional 229.1 million shares at the same price for the remaining $200 million, with expiration set for 30 days after the public release of Phase III ENSURE data or on February 17, 2031 [4] Clinical Development Plans - Proceeds from the placement will be used to complete ongoing Phase III ENSURE studies of vidofludimus calcium in relapsing multiple sclerosis (MS), with top-line results expected by the end of this year [2] - The company plans to submit a new drug application (NDA) in the US by mid-2027, targeting regulatory approval in 2028 [2] - Immunic also intends to launch a Phase III clinical program in primary progressive multiple sclerosis (PPMS) later this year, estimating that this trial will take approximately three-and-a-half to four years to complete [3] Strategic Leadership Changes - Immunic's co-founder and CEO Dr. Daniel Vitt will transition to a new executive role focused on scientific strategy and portfolio advancement, while the board will begin searching for a new CEO with expertise in MS commercialization [5]

Core Viewpoint - Immunic Inc (NASDAQ:IMUX) is experiencing a significant stock surge following the announcement of a private placement of up to $400 million, indicating strong investor confidence and potential for future growth [1]. Group 1: Financing Details - The financing round was led by existing investor BVF Partners, with participation from notable institutional investors including OrbiMed, RA Capital, Janus Henderson, Avidity Partners, and EcoR1 Capital [2]. - The structure of the deal includes $200 million upfront through pre-funded warrants priced at 87 cents each, with an additional potential $200 million contingent on the exercise of accompanying warrants [3]. Group 2: Use of Funds - The new capital is expected to sustain Immunic through late 2027, primarily funding the completion of Phase 3 ENSURE trials for vidofludimus calcium in relapsing multiple sclerosis, with top-line data anticipated by the end of 2026 [4]. - If the Phase 3 ENSURE trial results are positive, the company plans to file for regulatory approval in mid-2027, targeting a potential green light in 2028 [4]. - Additionally, the financing will enable Immunic to initiate a Phase 3 program in primary progressive multiple sclerosis (PPMS) later this year, with the study projected to last approximately three and a half to four years [5]. Group 3: Stock Performance - Following the announcement, Immunic shares rose by 26.43%, reaching a price of $1.10 at the time of publication [5].

Core Viewpoint - Immunic, Inc. has announced an oversubscribed private placement of up to USD 400 million to facilitate its transition into a commercial-stage company, focusing on the development of novel oral therapies for neurologic diseases, particularly multiple sclerosis [1][2]. Financing Details - The private placement will provide upfront proceeds of USD 200 million, with the potential for an additional USD 200 million through warrants [1][2]. - The financing was led by existing investor BVF Partners L.P. and included participation from various institutional investors [1][2]. - The company plans to use the net proceeds to fund clinical trials, operations, and general corporate purposes, with expectations to support activities through late 2027 [2]. Clinical Development Plans - Immunic aims to initiate a Phase 3 clinical program for primary progressive multiple sclerosis (PPMS) later this year, which is expected to take approximately 3.5 to 4 years to complete [1]. - The ongoing Phase 3 ENSURE trials for vidofludimus calcium in relapsing multiple sclerosis (RMS) are expected to yield top-line data by the end of 2026, with a New Drug Application (NDA) submission planned for mid-2027 [1][2]. Product Mechanism and Potential - Vidofludimus calcium is designed to provide neuroprotective effects and reduce inflammatory damage, addressing key biological drivers of disability progression in multiple sclerosis [1]. - The drug's mechanism involves enhancing neuronal survival through nuclear receptor-related 1 (Nurr1) activation and selective inhibition of dihydroorotate dehydrogenase (DHODH) [1]. Leadership Changes - Dr. Daniel Vitt, the co-founder and CEO, will transition to a new role focused on scientific strategy, while the search for a new CEO with commercial expertise in the MS space is underway [1][2]. - Simona Skerjanec has been appointed as the interim Chairperson of the Board of Directors, bringing significant experience from her previous role at Roche [1][2].

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists across key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered by the team includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Utilization - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company employs automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans to maintain best practices in content production and search engine optimization [5]